Fresenius Medical Care Names Shervin Korangy as New CEO
FMS is trading near its 52-week low of $20.02 (4.3% above the low) on elevated volume (2.8× avg).
Summary
Fresenius Medical Care has appointed Shervin Korangy as its new CEO, effective October 12, 2026. Korangy, who is also Chair of the Management Board, resigned from the Supervisory Board, and Ann Custin was identified as his successor, with court proceedings to be initiated to appoint her. Helen Giza, 58, is the outgoing CEO and Chair of the Management Board. The leadership change comes because the transformation achieved objectives, and the next phase needs a different profile. Korangy's strategic focus includes accelerating profitable growth, advancing innovation, and strengthening market leadership. The announcement comes as the stock trades near its 52-week low of $20.02, with shares at $20.89, following a period of strategic moves, including the recent China portfolio optimization and a share sale by parent Fresenius SE. Michael Sen is the Chairman of the Supervisory Board.
Updated with an SEC 6-K filing · What changed
Updates
· SEC 6-K — Korangy's appointment is effective October 12, 2026; he resigned from the Supervisory Board, and Ann Custin was identified as his successor.
- Leadership Change — Shervin Korangy is also Chair of the Management Board. Helen Giza, 58, is the outgoing CEO and Chair of the Management Board. The leadership change is because the transformation achieved objectives, and the next phase needs a different profile.
- Strategic Focus — Korangy's strategic focus includes accelerating profitable growth, advancing innovation, and strengthening market leadership.
- Supervisory Board — Michael Sen is the Chairman of the Supervisory Board. Court proceedings will be initiated to appoint Ann Custin to the Supervisory Board.
All 6 details
- Shervin Korangy is also Chair of the Management Board.
- Helen Giza, 58, is the outgoing CEO and Chair of the Management Board.
- Korangy's strategic focus includes accelerating profitable growth, advancing innovation, and strengthening market leadership.
- The leadership change is because the transformation achieved objectives, and the next phase needs a different profile.
- Michael Sen is the Chairman of the Supervisory Board.
- Court proceedings will be initiated to appoint Ann Custin to the Supervisory Board.
At the time of this announcement, FMS was trading at $20.89 on NYSE in the Life Sciences sector, with a market capitalization of approximately $12B. The 52-week trading range was $20.02 to $27.64. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.